Table 1 Currently approved immunotherapy combinations in cancer

Pembrolizumab + pemetrexed /platinum

First-line non-squamous NSCLC

May 10, 2017

[50, 296]

August 21, 2018

Chemoradiation followed by durvalumab

Stage III NSCLC

February 16, 2018

[86]

Chemotherapy and pembrolizumab

First-line NSCLC

October 30, 2018

[52]

Atezolizumab + bevacizumab, paclitaxel and carboplatin

First-line NSCLC

December 6, 2018

[297]

Atezolizumab + nab-paclitaxel/carboplatin

First-line Non-squamous NSCLC

December 3, 2019

[51]

Nivolumab + ipilimumab

First-line treatment of metastatic or recurrent NSCLC (PD-L1 >  = 1%)

May 15, 2020

[298]

Nivolumab + ipilimumab + 2 cycles of Pt chemo

First-line treatment of metastatic or recurrent NSCLC

May 26, 2020

[299]

Atezolizumab + etoposide/carboplatin

ES-SCLC

March 18, 2019

[53]

Durvalumab + chemo

Extensive SCLC

March 30, 2020

[54]

Nivolumab + ipilimumab

First-line advanced RCC

April 16, 2018

[300]

Axitinib + pembrolizumab

First-line advanced RCC

April 22, 2019

[301]

Avelumab plus axitinib

First-line advanced RCC

May 14, 2019

[302]

Nivolumab + cabozantinib

First-line advanced RCC

January 22, 2021

[303]

Chemotherapy, trastuzumab and pembrolizumab

Advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma

May 5, 2021

[304]

Chemotherapy + pembrolizumab

Locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma

March 23, 2021

[305]

Atezolizumab + nabpaclitaxel

Metastatic triple negative breast

March 8, 2019

[55]

Pembrolizumab + chemotherapy

Recurrent or metastatic triple negative breast

November 13, 2020

[56]

Pembrolizumab + chemotherapy

HNSCC

June 11, 2019

[57]

Pembrolizumab + lenvatinib

Endometrial carcinoma

September 17, 2019

[306]

Nivolumab + ipilimumab

Previously untreated unresectable malignant pleural mesothelioma

October 2, 2020

[307]

Nivolumab + ipilimumab

Hepatocellular carcinoma after Sorafenib

March 11, 2020

[308]

Atezolizumab + bevacizumab

HCC 1st-line

May 29, 2020

[309]

Nivolumab + ipilimumab

Salvage MSI-H/dMMR metastatic CRC

July 11, 2018

[310]

Nivolumab + ipilimumab

BRAF^WT Metastatic melanoma

October 1, 2015

[311]

Nivolumab + ipilimumab

Metastatic melanoma across BRAF status

January 23, 2016

[312]

Atezolizumab + cobimetinib and vemurafenib

BRAF V600 + advanced melanoma

July 30, 2020

[313]

Chemotherapy followed by avelumab

Locally advanced or metastatic urothelial carcinoma

June 30, 2020

[58]